VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
Filed with HKEX · Stock code 13 ·
6ix hasn’t read this filing yet.
View original source (HKEXnews)Company analysis
Earlier from Hutchmed (china)
- HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
- HUTCHMED Reports 2026 Interim Results
- HUTCHMED to Announce 2026 Half-Year Financial Results
- HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma